Hotz, Birgit <br/><br/>
Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.  [electronic resource] 

 -  Neoplasia (New York, N.Y.)  Oct 2010 
 - 797-806 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1476-5586 
<br/><br/><label>Standard No.: </label>10.1593/neo.10418  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--metabolism<br/>Animals<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Blotting, Western<br/>Cell Movement<br/>Cell Proliferation<br/>Cells, Cultured<br/>Combined Modality Therapy<br/>Deoxycytidine--analogs & derivatives<br/>Disease Models, Animal<br/>Endothelium, Vascular--cytology<br/>Humans<br/>Immunoenzyme Techniques<br/>Male<br/>Mice<br/>Mice, Nude<br/>Neoplasm Metastasis<br/>Neovascularization, Pathologic--prevention & control<br/>Pancreatic Neoplasms--metabolism<br/>RNA, Messenger--genetics<br/>Recombinant Fusion Proteins--metabolism<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Shiga Toxins--genetics<br/>Signal Transduction<br/>Survival Rate<br/>Vascular Endothelial Growth Factor A--genetics<br/>Vascular Endothelial Growth Factor Receptor-2--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays<br/>Gemcitabine